Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Launches Clinical Research of Platform for Prevention of COPD Exacerbations
September 19, 2019
- Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
- No Major Impact on Shionogi, Eisai from Purdue’s Bankruptcy Filing
September 18, 2019
- Fujifilm Grabs Rights to Cynata’s Cell Therapy for GVHD
September 18, 2019
- Enfortumab Vedotin Gets FDA Priority Review for Urothelial Cancer: Astellas/Seattle Genetics
September 18, 2019
- Mitsubishi Tanabe Grants Daiichi Sankyo Commercialization Rights for Edaravone in Brazil
September 18, 2019
- Astellas Ventures into Medical Device Arena with Iota Deal
September 17, 2019
- Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
- Eisai, Biogen Drop PIII Studies for Elenbecestat
September 17, 2019
- ViiV Files Anti-HIV Drug Combo Dovato in Japan
September 17, 2019
- Promotion Push Continues for Daiichi Sankyo’s Pain Drug Tarlige in July: Impact Track
September 13, 2019
- Takeda, PwC to Develop App for Crohn’s Disease
September 13, 2019
- MSD Files HIV-1 Drug Doravirine in Japan
September 13, 2019
- Chugai’s Satralizumab Hits Primary Target in PIII Study
September 13, 2019
- IT Startup Activaid Offers Clinical Trial Matching Service for IBD Patients through App
September 12, 2019
- Opdivo Showed 5-Year Survival Rates of 13.4% in 2nd-Line NSCLC in PIII Studies
September 12, 2019
- Fujifilm Rolls Out iPS Cell-Derived Small Intestinal Cell in Japan for Use in Assessing Drug Absorption
September 12, 2019
- Full Approval in Japan Will Be 1st Goal for Collategene: AnGes Chief
September 11, 2019
- Vital-Net Carving Out New Businesses in Regenerative Medicine, Robotics
September 11, 2019
- Keytruda Filed for Esophageal Cancer in Japan
September 11, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…